Rhinosinusitis

IDSA Rhinosinusitis Guidelines

IDSA Rhinosinusitis GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/88047

Contents of this Issue

Navigation

Page 7 of 11

Treatment Table 4. Antimicrobial Regimens for ABRS in Adults Indication First Line (Daily Dose) Initial empirical therapy Amoxicillin-clavulanate (500 mg/125 mg PO tid, or 875 mg /125 mg PO bid) β-lactam allergy Risk for antibiotic resistance or Second Line (Daily Dose) > Amoxicillin-clavulanate (2000 mg/125 mg PO bid) > Doxycycline (100 mg PO bid or 200 mg PO daily) > Doxycycline (100 mg PO bid or 200 mg PO daily) > Amoxicillin-clavulanate (2000 mg/125 mg PO bid) Failed initial therapy Severe infection requiring hospitalization > Ampicillin/sulbactam (1.5 g-3 g IV q6h) > Levofloxacin (500 mg PO daily) > Moxifloxacin (400 mg PO daily) > Levofloxacin (500 mg PO daily) > Moxifloxacin (400 mg PO daily) > Levofloxacin (500 mg PO or IV daily) > Moxifloxacin (400 mg PO or IV daily) > Ceftriaxone (1-2 g IV q24h) > Cefotaxime (2 g IV q4-6 h)

Articles in this issue

Archives of this issue

view archives of Rhinosinusitis - IDSA Rhinosinusitis Guidelines